RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Studying metformin in Parkinson’s

Researchers investigate metformin as a treatment approach in people with Parkinson’s.

Testing a treatment or activity · Study reference: NCT07229651

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported actual date)
2025-11-10
Main measurements finished (planned)
2026-11-20
Study finished (planned)
2027-09-20

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Ages 50 years to 70 years · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: Eligible participants were men and women aged 50 years or older with a confirmed diagnosis of PD Patients receiving levodopa/carbidopa therapy. Exclusion Criteria: Secondary causes of parkinsonism Patients taking anti-inflammatory drugs Atypical parkinsonian syndromes Prior stereotaxic surgery for Parkinson's disease Pregnancy and lactation Cardiovascular disease patients Patients with coagulation disorders Suffering from active malignancy Addiction to alcohol and / or drugs Known allergy to the studied medications
Full study name & original research details

Official study title

Safety and Efficacy of Metformin in Patients With Parkinson Disaese

Short title used by the registry

Metformin in Parkinson Disease

Original description

The clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum

Conditions reported: Parkinson Disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Interventional
Interventions
Levodopa Carbidopa; Metformin
Phases
PHASE2; PHASE3
Sponsor
Tanta University
Start date reported by registry
2025-11-10 (actual)

Registry updated: 2025-11-21 · Status last verified by the registry submitter: 2025-11

Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

No central contact is listed. Check the location contacts or the official registry record.

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Tanta University

Tanta, Egypt

Recruiting

Ihab Elsayed Hassan, MSC · 01067831661 · ihassan@horus.edu.eg

Facility not reported

Egypt

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.